A tablet taken by mouth, it causes the body to boost the activity of a second gene, called SMN2, which also carries the instructions for building SMN protein but typically makes less than SMN1.

The new tablet, expected to be available in the coming weeks, is suitable for people two years of age or older who weigh more than 20 kgs (44 lbs). Roche leads the clinical development of Evrysdi as ...

“The Evrysdi tablet combines established efficacy with ... About Evrysdi ® (risdiplam) Evrysdi is a survival motor neuron 2 (SMN2) pre-mRNA splicing modifier designed to treat SMA caused ...